For effective implementation of the Pharmaceutical Quality System, more than mere procedures and documents is required. Leadership accountability of the pharmaceutical quality system requires management not only to be in charge of quality but also to make investments in its success. The 2026 leaders should integrate ICH Q10 principles into the framework of digital and […]

An effective PQS requires an effective system for detection of quality problems, investigation and correction of their cause, and change control. The Efficient CAPA system in line with ICH Q10 will allow the manufacturer to resolve repeat issues and promote continuous improvement. Integration of CAPA and Change Management within ICH Q10 and ICH Q12 will […]

When pharmaceutical companies use digital technology and AI to analyze quality control procedures and support data-driven decision-making, regulatory requirements become increasingly important. In 2026, the new regulations of EU GMPs will lead to the need for more focus on lifecycle management of computerized systems, data integrity, cybersecurity, and AI governance. The improved version of Annex […]

In 2026, pharmaceutical manufacturers are now going above and beyond simple cGMP compliance by adopting more forward-thinking and robust quality systems. The concept of FDA Quality Management Maturity (QMM) for 2026 is based on the extent to which quality management principles can be applied to process improvement and risk management for the maintenance of quality […]

There is a need for a systematic process for quality risk management across the product lifecycle for pharmaceutical companies. The implementation of ICH Q9 (R1) would enable organizations to develop good decision-making processes, objectivity, and a link between quality risk management and routine PQS operations. By 2026, quality risk management integrated with technology, scientific knowledge, […]

Quality, safety, and efficacy of pharmaceutical products rely on the appropriate storage and transportation conditions. Organisations having a Wholesale Distribution Authorisation (WDA) should prove that medicines are stored and distributed within the approved temperature ranges. Proper temperature mapping and cold chain WDA procedures assist in identifying environmental risks, proving that storage and distribution conditions are valid, ultimately leading to compliance with Good Distribution Practice. A proper validation programme will lead to […]

Nitrosamine risk management remains a major regulatory focus for pharmaceutical manufacturers. Although most companies have a formal risk assessment process, inspection findings are frequently due to poor scientific evidence rather than absent documentation. A solid nitrosamine scientific justification in pharma practices means that the organisation needs to underpin each individual point with good data, reasoned arguments, and up-to-date regulatory knowledge. Good scientific justification will aid […]

The European pharmaceutical industry is entering a new compliance phase with separate GMP requirements for human and veterinary medicinal products. Organisations manufacturing both product types must understand how these regulatory changes affect their quality systems. The human vs veterinary GMP split means companies will have to review documentation, manufacturing and operations to remain compliant. Early […]

Deviation Management vs. CAPA: Where Most Quality Teams Fail During Audits The pharmaceutical industry is required to have robust quality systems to deal with Governmental regulatory expectations and to safeguard product quality. Yet, a lot of audit observations arise from teams not understanding the distinction between deviation management vs CAPA. Although interconnected, they are not […]

MHRA Inspection Readiness: What Inspectors Look For in 2026 If you want to remain compliant in the UK pharmaceutical region, it’s not just a matter of ‘getting ready’ at the last minute prior to a Pharmacovigilance inspection. The standards are changing and increasing in rigor as inspectors focus upon the quality system, data integrity and ongoing compliance. Good MHRA inspection readiness enables […]